Renal Transplantation in Systemic Lupus Erythematosus: Outcome and Prognostic Factors in 50 Cases from a Single Centre
Table 1
Demographic and clinical characteristics, histological and immunologic features, and treatments used in the cohort of SLE transplanted patients.
Demographic characteristics
Gender female
32 (80%)
Ethnicity
Caucasians
38 (95%)
Hispanics
2 (5%)
Age at SLE diagnosis (years)
22.7 ± 10.5
Age at renal transplantation (years)
36 ± 10.4
Time between SLE diagnosis and lupus nephritis (months)
28.4 ± 65.1
Time between lupus nephritis and onset of dialysis (months)
68.8 ± 72.3
Time on dialysis (months)
50 ± 49.4
Time between diagnosis of lupus nephritis and transplantation (months)
118 ± 69
Time of followup (months)
71.4 ± 41
Histological diagnosis at onset of lupus nephritis:
Type IV
26 (72%)
Type III
3 (8%)
Type II
2 (5%)
Type V
2 (5%)
Type VI
1 (3%)
Interstitial nephritis
1 (3%)
Thrombotic microangiopathy
1 (3%)
Unknown
4 (10%)
Number of transplantations
First transplantation
34 (68%)
Second transplantation
12 (24%)
Third transplantation
4 (8%)
Donor source
Cadaveric donor
29 (58%)
Living donor
21 (42%)
HLA identical siblings
4 (19%)
Other genetically related
13 (62%)
Unrelated donors
4 (19%)
Immunologic features at renal transplantation
Antinuclear antibodies
50 (100%)
Anti-dsDNA antibodies
30 (60%)
Anti-phospholipid antibodies
12 (63%)
Treatments
Cyclosporine/tacrolimus
19/27
Azathioprine/mycophenolic acid
6/38
Sirolimus
3
ATG/OKT3/Basiliximab/no induction
23/1/9/17
Graft failure (%)
15 (30%)
Quantitative variables are presented as mean ± standard deviation and qualitative variables as number (percentage). Treatments are presented as number of transplantations.
SLE: systemic lupus erythematosus; ATG: antithymocyte globulin; OKT3: orthoclone.
